Advances in the First-Line Treatment of Anemia Associated With Lower-Risk Myelodysplastic Syndromes (LR-MDS): Phase 3 COMMANDS Trial Data

Amer Zeidan, MBBS, discusses the signs and symptoms of lower-risk MDS and the tests typically used for diagnosis.

Dr Amer Zeidan explains the criteria he uses to assess risk in MDS, and why it is important to initiate treatment for lower-risk patients early.

Amer Zeidan, MBBS, explains the treatment options for patients with lower-risk MDS prior to the approval of luspatercept.

Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.

Amer Zeidan, MBBS, closes his discussion with a look at the potential implications of the COMMANDS trial data on the treatment of lower-risk MDS in clinical practice.